We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $261K invested in XTL Biopharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.22% less ownership

Funds ownership: 2.82% → 2.59% (-0.22%)

13% less capital invested

Capital invested by funds: $299K → $261K (-$37.6K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$7.65K
2
UBS Group
UBS Group
Switzerland
+$1.62K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$31.3K
2
Morgan Stanley
Morgan Stanley
New York
-$2.72K

XTLB Hedge Fund Activity: Q2 2025 in Review

4 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2025, worth a combined $261K — down 13% from $299K a quarter earlier.

Fund positioning in XTLB was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was RhumbLine Advisers, adding an estimated $7.65K. The largest seller was Citadel Advisors, exiting entirely with an estimated $31.3K sold.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $261K of XTL Biopharmaceuticals stock for Q2 2025, down 13% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q2 2025 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q2 2025 was RhumbLine Advisers, an estimated $7.65K added.
  • The largest XTL Biopharmaceuticals seller in Q2 2025 was Citadel Advisors, an estimated $31.3K sold.

Based on aggregated 13F filings for Q2 2025.